Aktienanalyse zu Beyondspring Inc (BYSI)BYSIBeyondspring Inc

BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Beyondspring Inc is not a good buy right now due to its current price of $0.601, a 52-week low of $0.42, and a troubling trend of negative earnings with a projected EPS of -0.05 for Q1 2026. The company has also experienced a significant year-to-date change of -62.67%, indicating a lack of investor confidence and potential liquidity issues. The main risk is the ongoing negative net income, which reached -$2,159,000 in Q1 2026, raising concerns about financial stability.

2 analysts cover BYSI: 2 rate it Buy, 0 Hold and 0 Sell.